Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
about
Possible neurocognitive benefits of exercise in persons with heart failureUncovering heart failure with preserved ejection fraction in patients with type 2 diabetes in primary care: time for a changeAddressing Major Unmet Needs in Patients with Systolic Heart Failure: The Role of IvabradineProposed guidelines for the diagnosis and management of methylmalonic and propionic acidemiaThe risk of heart failure associated with the use of noninsulin blood glucose-lowering drugs: systematic review and meta-analysis of published observational studiesArrhythmia risk associated with sleep disordered breathing in chronic heart failureHeart failure with preserved ejection fractionManaging therapeutic competition in patients with heart failure, lower urinary tract symptoms and incontinenceEvaluating the scripts and thresholds of general practitioners for diagnosing heart failure in elderly peopleTailoring of self-management interventions in patients with heart failureRAAS inhibitors and cardiovascular protection in large scale trials.Aliskiren: review of efficacy and safety data with focus on past and recent clinical trials.Risk-adjustment models for heart failure patients' 30-day mortality and readmission rates: the incremental value of clinical data abstracted from medical charts beyond hospital discharge record[Ventricular tachycardia : Treatment and prognostic significance].Cardiac aging and heart disease in humansThe past, present and future of renin-angiotensin aldosterone system inhibitionTargeting Sleep Disordered Breathing to Prevent Heart Failure: What is the Evidence?Effect of vitamin-D analogue on albuminuria in patients with non-dialysed chronic kidney disease stage 4-5: a retrospective single center study.Early administration of levosimendan is associated with improved kidney function after cardiac surgery - a retrospective analysis.Emerging biomarkers in heart failure and cardiac cachexiaEvaluation of a self-management patient education program for patients with chronic heart failure undergoing inpatient cardiac rehabilitation: study protocol of a cluster randomized controlled trial.Heart failure and atrial fibrillation: from basic science to clinical practiceRenin inhibitors in diabetes and hypertension: an update.Relation between E/e' ratio and NT-proBNP levels in elderly patients with symptomatic severe aortic stenosis.Health state utilities associated with major clinical events in the context of secondary hyperparathyroidism and chronic kidney disease requiring dialysisCharacteristic cardiac phenotypes are detected by cardiovascular magnetic resonance in patients with different clinical phenotypes and genotypes of mitochondrial myopathy.Loop diuretics in acute heart failure: beyond the decongestive relief for the kidneyIschemic aetiology, self-reported frailty, and gender with respect to cognitive impairment in chronic heart failure patientsDo heart failure status and psychosocial variables moderate the relationship between leisure time physical activity and mortality risk among patients with a history of myocardial infarction?Rationale and design of a randomized, controlled multicentre clinical trial to evaluate the effect of bromocriptine on left ventricular function in women with peripartum cardiomyopathy.Prevalence of airflow obstruction in patients with stable systolic heart failure.Serum neutrophil gelatinase-associated lipocalin has an advantage over serum cystatin C and glomerular filtration rate in prediction of adverse cardiovascular outcome in patients with ST-segment elevation myocardial infarction.Perceived Benefits of Implantable Cardioverter Defibrillator Implantation among Heart Failure Patients and Its Relation to Quality of Life: A Cross-Sectional StudyRAS-Mediated Adaptive Mechanisms in Cardiovascular Tissues: Confounding Factors of RAS Blockade Therapy and Alternative Approaches.Endocardial Remodeling in Heart Failure Patients with Impaired and Preserved Left Ventricular Systolic Function--A Magnetic Resonance Image StudyAliskiren effect on plaque progression in established atherosclerosis using high resolution 3D MRI (ALPINE): a double-blind placebo-controlled trial.Dual renin-angiotensin system inhibition for prevention of renal and cardiovascular events: do the latest trials challenge existing evidence?Single-pill combinations: a therapeutic option or necessity for vascular risk treatment?Effects of antihypertensive drugs on arterial stiffnessRationale and design of a randomized, double-blind, placebo controlled multicenter trial to study efficacy, security, and long term effects of intermittent repeated levosimendan administration in patients with advanced heart failure: LAICA study.
P2860
Q26766657-CAA0B12F-A3D2-4812-8EDB-5C5DC368D94AQ26767122-0954F1F4-C5FF-4EF5-A2BA-D5F07419EE78Q26773370-45CCE6A4-CC21-427A-AC19-90BFD034C9C1Q26865440-6B307A66-FC38-4682-B791-B456DD21C06CQ26999933-2437BD5A-D9DA-4243-A693-0DDEF61D74E4Q27012633-2EF307A3-AE1B-4F1D-89D0-3C8484EE45EFQ27024008-68443F30-0971-41C7-8F1F-7F2BC53DBAE5Q27027072-622EBB23-077F-4563-BCBA-44DE921666E1Q27313720-D10F7BEC-A9CB-43CE-B476-A7296C5C3D34Q28393588-FE0FA690-75B2-4F99-8062-F498CAAC2D7EQ30424541-51C67CBD-645E-4288-8322-4E1E5BE5E891Q30664624-BB80811A-C55C-401C-96F3-559471C54FEFQ31127047-B5B7EAA8-5246-4D42-8A73-2860DE6B24DEQ33163466-D50DB684-59C9-45E0-8FAB-7C00AC3B76F1Q33639771-5FC2E8AD-CDA4-4CE0-B64C-4C531D42C3EAQ34094354-AEEC76C4-8950-43FC-9B41-BFEA3141B537Q34149155-1D8456F2-A31F-40EF-8F9B-FBA4447F0ACDQ34408823-A8FAB675-40D4-42DA-9542-83EFF5A7637CQ34558248-CEFEB3AD-97F7-4BA2-8EFC-9DF2CAE58801Q34836097-CD04E129-11F2-447A-A46C-3AA23B9E1E56Q34966796-E53E15F8-C6E0-4B77-A1A5-73506615F3BDQ35138993-33723BAE-E543-48DD-832E-CE605A3422F3Q35728190-4EBCB3AD-942F-4932-98C9-2A8CB93EF2C3Q35785968-89CA4234-7D71-4B1F-97CB-11DAC478D47DQ35804097-6F037E4F-E9F1-40B5-9CD0-C2AFAE9537E0Q35814768-3539178E-BBF5-47AC-9833-53DAD14F8515Q36024026-001476D7-88BC-44F6-9089-3B21C1A10C71Q36117728-F50FA3A6-467C-4AC8-861F-E36576B5FA59Q36161706-FA864DD7-F8FB-4D17-A856-E0501C942E72Q36214915-863BCF8A-F3FE-4185-BF11-94957656BE57Q36243275-361F7EDB-85CA-4B53-ABD5-9EF5FA855646Q36309580-65D3B94F-3F8A-45BD-B90D-F1D2DDC8678CQ36363146-53711F6E-AAF1-429A-989E-8B2D05158BA6Q36551388-E8C91475-24B2-419C-BD4A-F4E7F06D62F3Q36579775-608756A9-08A1-4CF0-A98B-E80DF97BE4FCQ36974370-C9F26CA3-3A10-4F73-B532-2AA056FF96F5Q37053287-FCF37406-70A6-4AE4-B2D9-57479947AD11Q37077196-63B68C6E-01C7-4D46-85F3-926B48C816B2Q37277071-F259CDAE-F527-44FB-B93F-76F4E7C85A05Q37314355-FF064A09-2252-465A-B2ED-531423CC3A73
P2860
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@en
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@nl
type
label
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@en
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@nl
prefLabel
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@en
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@nl
P2093
P2860
P50
P921
P356
P1476
Aliskiren, ALTITUDE, and the implications for ATMOSPHERE.
@en
P2093
Barry M Massie
John J V McMurray
William T Abraham
P2860
P304
P356
10.1093/EURJHF/HFS033
P5008
P577
2012-04-01T00:00:00Z